Lymphoma (tissue type)
Cancer of lymphocytes, the white blood cells of the immune system, usually growing as masses in lymph nodes, spleen or other organs. Divided into Hodgkin and the many non-Hodgkin types.
Most lymphomas arise from B cells and keep surface markers such as CD19, CD20 and CD30, which has made them the proving ground for antibody therapy (rituximab, 1997), ADCs (brentuximab vedotin), CAR-T (axicabtagene, 2017) and bispecific T-cell engagers (glofitamab); diffuse large B-cell lymphoma is the commonest type and is often curable with chemo-immunotherapy. Hodgkin lymphoma, defined by its Reed-Sternberg cells, is highly curable and exceptionally responsive to PD-1 blockade. Lymphomas and leukaemias overlap: the same malignant lymphocyte can present as a mass (lymphoma) or circulate in the blood (leukaemia).
Pages like this
not linked directly; found by shared links- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
Shares Glofitamab, Axicabtagene ciloleucel, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'Orsola
Shares Glofitamab, CD20, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TermImmune system
Shares Lymph node, B cell, Antibody, T cell.
- TermAntigen
Shares Antibody, T cell, CD19, T-cell engagers (bispecific).
- TermRichter transformation
Shares Glofitamab, T-cell engagers (bispecific), Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- InstitutionLYSA – The Lymphoma Study Association
Shares Glofitamab, Axicabtagene ciloleucel, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- PersonFrederick L. Locke
Shares Axicabtagene ciloleucel, CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- TrialSTARGLO
Shares Glofitamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.